Price$0.89+0.00 (+0.11%)
05:45 PM07:15 PM
News · 26 weeks47-53%
2025-11-022026-04-26
Mix3690d
- Insider20(56%)
- SEC Filings10(28%)
- Other3(8%)
- Earnings2(6%)
- Leadership1(3%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Sharp John P3 - Skye Bioscience, Inc. (0001516551) (Issuer)
- SECSEC Form DEFA14A filed by Skye Bioscience Inc.DEFA14A - Skye Bioscience, Inc. (0001516551) (Filer)
- SECSEC Form DEF 14A filed by Skye Bioscience Inc.DEF 14A - Skye Bioscience, Inc. (0001516551) (Filer)
- PRSkye Bioscience Presenting at GLP-1-Based Therapeutics SummitSAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye") a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present at the GLP-1-Based Therapeutics Summit in Boston, MA, being held April 14-16. Presentation Details Title: Maximizing Efficacy, Minimizing Risk by Leveraging Peripheral CB1 Antagonism in Combination with GLP-1 Agonists to Advance the Obesity Treatment Paradigm Presenter: Punit Dhillon, President & CEO Date: Thursday, April 16, 2026 Time: 1:30 pm About Nimacimab Nimacimab is a potential first-in-class, peripherally-restricted monoclonal antibody inhi
- SECSEC Form PRE 14A filed by Skye Bioscience Inc.PRE 14A - Skye Bioscience, Inc. (0001516551) (Filer)
- SECSEC Form PREM14A filed by Skye Bioscience Inc.PREM14A - Skye Bioscience, Inc. (0001516551) (Filer)
- SECAmendment: SEC Form 8-K/A filed by Skye Bioscience Inc.8-K/A - Skye Bioscience, Inc. (0001516551) (Filer)
- SECSkye Bioscience Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Skye Bioscience, Inc. (0001516551) (Filer)
- INSIDERSEC Form 4 filed by Smith Karen L.4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- INSIDERSEC Form 4 filed by Twitty Christopher4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- INSIDERSEC Form 4 filed by Jenkins Annalisa4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Diep Tuan Tu3/A - Skye Bioscience, Inc. (0001516551) (Issuer)
- INSIDERSEC Form 4 filed by Charych Deborah H.4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- INSIDERSEC Form 4 filed by Grayson Paul A.4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- INSIDERSEC Form 4 filed by Schwab Andrew J.4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- INSIDERSEC Form 4 filed by Diep Tuan Tu4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- INSIDERSEC Form 4 filed by Dhillon Punit4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- PRSkye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination DevelopmentSAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye") a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, has treated the first patient in its Part C expansion study of the CBeyond Phase 2a trial to characterize safety and pharmacokinetics (PK) at exposures designed to challenge the peripheral restriction of nimacimab through intravenous (IV) administration over 16 weeks of treatment. These doses will set the benchmark for the safety profile of nimacimab and support higher dosing in combination with incretin therapies. The expansion study comprises two cohorts of nimacim
- SECSEC Form 8-K filed by Skye Bioscience Inc.8-K - Skye Bioscience, Inc. (0001516551) (Filer)
- SECSkye Bioscience Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Skye Bioscience, Inc. (0001516551) (Filer)
- SECSEC Form 10-K filed by Skye Bioscience Inc.10-K - Skye Bioscience, Inc. (0001516551) (Filer)
- PRSkye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateInitiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg IV cohorts;Received written FDA Type C meeting minutes; feedback is informing key Phase 2b combination design elements and the Company's ongoing evaluation of a potential add-on development path with incretin therapy;Presented new body composition data demonstrating differentiated weight maintenance profile for patients that have discontinued combination therapy;Proof-of-concept preclinical data validates Skye's antigen-peptide conjugate platform, a single unimolecular therapeutic of nimacimab-GLP1RA that delivers additive weight-loss. SAN DIEGO, Ma
- PRSkye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Tuesday, March 10th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 fourth quarter and full-year financial results and business update. An earnings press release will be issued after the market closes on March 10th. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to
- SECSEC Form 8-K filed by Skye Bioscience Inc.8-K - Skye Bioscience, Inc. (0001516551) (Filer)
- INSIDERSEC Form 4 filed by Director Schwab Andrew J.4 - Skye Bioscience, Inc. (0001516551) (Issuer)
SKYE FAQ
5 questionsWhere does SKYE stock trade?
Skye Bioscience Inc. (SKYE) is listed on NASDAQ.What sector and industry is SKYE in?
Skye Bioscience Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about SKYE?
Skye Bioscience Inc. has had 8 recent analyst actions on file. The most recent action was from Craig Hallum: Hold with a $200.00 price target on 2025-10-06.What companies are similar to SKYE?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare SKYE side-by-side with any of them on Quantisnow.How can I track SKYE on Quantisnow?
Quantisnow aggregates Skye Bioscience Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SKYE to receive live email and push alerts on every new disclosure.